When it comes to PD-1 inhibitors, in spite of a tendency of high PD-L1 expression in BRAF mutant NSCLC, there is no correlation between PD-L1 expression and drug efficacy [107]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.